ImmunityBio director granted 65,600 stock options

ImmunityBio director Wendel Bruce received a new stock option grant as part of his compensation.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ImmunityBio director Wendel Bruce received a new stock option grant as part of his compensation. He was awarded options covering 65,600 shares of ImmunityBio common stock at an exercise price of $7.25 per share, with no cash paid at grant.

These options vest 100% on the earlier of June 9, 2027 or the date immediately before the next annual stockholder meeting, as long as he continues as a service provider under the company’s 2025 Equity Incentive Plan. The options expire on June 9, 2036, giving a long-term incentive tied to the company’s share price.

Insider Trade Summary

Grant/Award: 65,600 shares

Grant/Award 1 txn

Insider Wendel Bruce

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	65,600	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 65,600 contracts (Direct)

Footnotes (1)

F1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Key Figures

Options granted: 65,600 options Exercise price: $7.25 per share Vesting date: June 9, 2027 +2 more

5 metrics

Options granted 65,600 options Stock Option (right to buy) granted to director

Exercise price $7.25 per share Strike price for 65,600 option shares

Vesting date June 9, 2027 Cliff vesting or earlier date before next annual meeting

Expiration date June 9, 2036 Option term end for granted award

Derivative holdings after grant 65,600 options Total stock options held following this transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, 2025 Equity Incentive Plan, Service Provider

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

2025 Equity Incentive Plan financial

"defined in the Issuer's 2025 Equity Incentive Plan"

Service Provider financial

"continuing to be a Service Provider through such applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ImmunityBio (IBRX) director Wendel Bruce report in this Form 4?

Wendel Bruce reported receiving a stock option grant for 65,600 shares of ImmunityBio common stock. The award is compensation-based, carries a fixed exercise price, and vests in the future subject to continued service, rather than reflecting an open-market share purchase or sale.

How many ImmunityBio (IBRX) options were granted to Wendel Bruce and at what price?

He was granted options on 65,600 underlying shares with an exercise price of $7.25 per share. This gives him the right, but not the obligation, to buy ImmunityBio common stock at that price once the options vest and before they expire.

When do Wendel Bruce’s new ImmunityBio (IBRX) stock options vest?

All 65,600 option shares vest 100% on the earlier of June 9, 2027 or the date immediately preceding ImmunityBio’s next annual stockholder meeting. Vesting requires that he continues to serve as a “Service Provider” under the company’s 2025 Equity Incentive Plan.

When do the ImmunityBio (IBRX) stock options granted to Wendel Bruce expire?

The options expire on June 9, 2036, giving a 10-year term from grant. After the expiration date he can no longer exercise them, even if they had vested, so any potential value depends on ImmunityBio’s share price before that date.

Did Wendel Bruce buy or sell ImmunityBio (IBRX) shares in the market?

The filing shows a grant of stock options as compensation, not an open-market purchase or sale of shares. The transaction code is a grant or award, meaning he received options at no cost instead of trading existing ImmunityBio stock in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/10/2026 - 08:11 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wendel Bruce

(Last)

(First)

(Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$7.25	06/09/2026		A		65,600		⁽¹⁾	06/09/2036	Common Stock	65,600	$0	65,600	D

Explanation of Responses:

1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Remarks:

	/a/ David C. Sachs, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR